Related Experiment Video
Updated: Apr 17, 2026

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
Cytokine-induced monocyte MMP-1 is negatively regulated by GSK-3 through a p38 MAPK-mediated decrease in ERK1/2 MAPK
1National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.
Abstract:
Elucidation of the signal transduction events leading to the production of MMPs by monocytes/macrophages may provide insights into the mechanisms involved in the destruction of connective tissue associated with chronic inflammatory lesions. Here, we show that GSK-3 is a negative regulator of cytokine-induced MMP-1 production by monocytes. Inhibition of monocyte GSK-3 pharmacologically with SB216763 or GSK-3β siRNA caused a significant enhancement of MMP-1 by TNF-α- and GM-CSF-activated monocytes, indicating that induction of MMP-1 by TNF-α and GM-CSF involved phosphorylation/inactivation of GSK-3. TNF-α- and GM-CSF-induced phosphorylation of GSK-3 and subsequent MMP-1 production was blocked with the PKC inhibitor Gö6976 but not by the AKT1/2 inhibitor AKT VIII, showing that cytokine phosphorylation of GSK-3 occurs primarily through a PKC pathway. Inhibition of GSK-3 resulted in decreased phosphorylation of p38 MAPK with a corresponding increase in phosphorylation of ERK1/2 MAPK. Enhanced MMP-1 production by treatment with SB216763 was a result of increased ERK1/2 activation, as demonstrated by inhibition of MMP-1 by PD98059, a specific ERK1/2 inhibitor. Conversely, the p38 MAPK inhibitor SB203580 enhanced cytokine activation of ERK1/2 and the production of MMP-1 similar to that of SB216763. These findings demonstrate that the degree of cytokine-mediated phosphorylation/inhibition of GSK-3 determines the level of MMP-1 production through a mechanism involving decreased activation of p38 MAPK, a negative regulator of ERK1/2 required for cytokine-induced production of MMP-1 by monocytes.
Insights
Glycogen synthase kinase-3 (GSK-3) negatively regulates monocyte production of matrix metalloproteinase-1 (MMP-1). Inhibiting GSK-3 enhances MMP-1, revealing a novel pathway involving protein kinase C (PKC) and mitogen-activated protein kinases (MAPKs).
Area of Science:
- Immunology
- Cell Biology
- Biochemistry
Background:
- Monocytes/macrophages produce matrix metalloproteinases (MMPs), enzymes implicated in connective tissue destruction during chronic inflammation.
- Understanding the signal transduction pathways regulating MMP production is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of Glycogen synthase kinase-3 (GSK-3) in regulating cytokine-induced MMP-1 production by monocytes.
- To elucidate the specific signaling pathways, including mitogen-activated protein kinases (MAPKs) and protein kinase C (PKC), involved in this process.
Main Methods:
- Monocytes were treated with tumor necrosis factor-alpha (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the presence or absence of GSK-3 inhibitors (SB216763, GSK-3β siRNA), PKC inhibitors (Gö6976), AKT inhibitors (AKT VIII), and MAPK inhibitors (PD98059, SB203580).
- Production of MMP-1 was quantified.
- Phosphorylation levels of GSK-3, p38 MAPK, and ERK1/2 MAPK were assessed.
Main Results:
- Inhibition of GSK-3 significantly enhanced TNF-α- and GM-CSF-induced MMP-1 production.
- Cytokine-induced GSK-3 phosphorylation and subsequent MMP-1 production were mediated primarily by a PKC pathway.
- GSK-3 inhibition led to decreased p38 MAPK phosphorylation and increased ERK1/2 MAPK phosphorylation, with ERK1/2 activation being essential for enhanced MMP-1 production.
- Conversely, p38 MAPK inhibition mimicked GSK-3 inhibition effects on ERK1/2 activation and MMP-1 production.
Conclusions:
- GSK-3 acts as a negative regulator of cytokine-induced MMP-1 production in monocytes.
- The PKC-GSK-3-MAPK signaling axis, specifically the interplay between p38 MAPK and ERK1/2, dictates the level of MMP-1 production.
- Targeting GSK-3 or modulating downstream MAPK pathways may offer therapeutic strategies for inflammatory conditions characterized by excessive connective tissue degradation.
Related Concept Videos
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Inhibition of Cdk Activity
Differentiation of Common Myeloid Progenitor Cells
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Role of Matrix Metalloproteases in Degradation of ECM

